Cognition Therapeutics Announces Dosing of First Patient in

NEW YORK, July 11, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has dosed the first participant in the Phase 2 MAGNIFY study of CT1812, an

Related Keywords

United States , Daniel Kontoh Boateng , Lisa Ricciardi , David Rp Almeida , Aline Sherwood , Scienta Communications , Securities Exchange Commission , Nasdaq , Tiberend Strategic Advisors Inc , Cognition Therapeutics Inc , Erie Retinal Surgery , Cognition Therapeutics , Geographic Atrophy Secondary , Private Securities Litigation Reform Act , Strategic Advisors , Region ,